US Zulassung + Partnerschaft in 2010 = TOP PICK

Seite 1 von 2
neuester Beitrag: 27.07.17 17:21
eröffnet am: 11.03.10 18:59 von: Biotechmaste. Anzahl Beiträge: 41
neuester Beitrag: 27.07.17 17:21 von: centsucher Leser gesamt: 11970
davon Heute: 3
bewertet mit 4 Sternen

Seite: 1 | 2  

11.03.10 18:59
4

205 Postings, 4703 Tage BiotechmasterUS Zulassung + Partnerschaft in 2010 = TOP PICK

Diese Aktie gehört wohl zu den günstigsten Biotechs überhaupt aber am besten macht eure Hausaufgaben selbst und ihr werdet staunen .

Hier hat man die Chance wirklich sehr gutes geld zu verdienen .


IntelliPharmaceutics (IPCI)

Marktkap: 17 Mio$
Cash: 8 Mio$
Kurs: 1,50 $

Shares Out: 10,9 M


Pipeline
http://www.intellipharmaceutics.com/pipeline.cfm


Präsentation März 2010
http://files.shareholder.com/downloads/...b7/Intellipharmaceutics.pdf


Intellipharmaceutics' development milestones for 2010 include the following:

-- Potential conclusion of the ongoing litigation process and/or FDA
approval of Focalin XR

-- File and have accepted for review by the FDA, two additional ANDA applications

-- Establish at least one additional development/marketing alliance

-- Complete successful manufacturing of clinical batches of Rexista(TM)

-- Complete Phase 1 studies using clinical batches of Rexista(TM)

-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical
development plan  
Seite: 1 | 2  
15 Postings ausgeblendet.

01.07.15 13:47
1

32 Postings, 2757 Tage retti1977Wann starten wir durch?

Can Intellipharmaceutics International Inc. (NASDAQ:IPCI) Keep Up with Analyst Expectations?

on June 30, 2015  
http://www.investornewswire.com/analyst-views/...-expectations/17276/  

09.07.15 13:28
1

32 Postings, 2757 Tage retti1977Gute News!

Monster News!

the United States Food and Drug Administration ("FDA") has indicated to the Company that it has rescinded its previous requirement that the Company meet newly-imposed conditions for bioequivalence prior to receiving final approval for the Company?s tentatively-approved strengths of its generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules (the ?Product?). The strengths affected include 5 mg, 10 mg, 20 mg and 40 mg. The already-approved 15 mg and 30 mg strengths now in the market are not affected.

 

09.07.15 15:27
1

32 Postings, 2757 Tage retti1977wie weit geht heut die Reise?

15.07.15 18:06
1

32 Postings, 2757 Tage retti1977Wir steigen und steigen!

Bald die 4$ Marke!!!  

12.01.16 16:04

41046 Postings, 3244 Tage wallanderIPCI $2.26

interessant... +50% sollten drinn sein oder, m.M.  
Angehängte Grafik:
ipci.png (verkleinert auf 73%) vergrößern
ipci.png

12.01.16 16:07

41046 Postings, 3244 Tage wallanderauf Jahressicht :-)

14.01.16 17:22

41046 Postings, 3244 Tage wallanderTH $2.74

25.02.16 22:25

41046 Postings, 3244 Tage wallanderna sieh mal einer an, löppt ja :-)

prima... $$$  
Angehängte Grafik:
ipci2.png (verkleinert auf 72%) vergrößern
ipci2.png

26.04.16 09:47

22329 Postings, 4615 Tage Balu4uGeht was?

08.06.16 12:28

728 Postings, 3063 Tage Poldi278Anda's

Bis wann sollen eigentlich diese Anträge von 2010/11 genehmigt werden?In 2020 oder was?Verstehen muss man das nicht oder?  

17.10.16 22:25

150 Postings, 3789 Tage RainbowfuTut sich schwer

spricht prinzipiell gar nichts gegen die Aktie. Nur der Kurs macht ne pause  

19.10.16 17:03

150 Postings, 3789 Tage RainbowfuEnde

02.11.16 17:21

150 Postings, 3789 Tage RainbowfuKurz

vor dem Start  

10.11.16 22:05

998 Postings, 2933 Tage Max_V....läuft schön langsam an...

IntelliPharmaCeutics International Has Huge Upside With Limited Downside

http://seekingalpha.com/article/...ional-huge-upside-limited-downside

 

14.11.16 10:48
1

998 Postings, 2933 Tage Max_V.Kommt diese Woche die News zum

PODRAS Patent? Ich denke schon...

Patent status: Application Is Considered Ready for Issue

Control Number: 14/790101

http://portal.uspto.gov/pair/PublicPair
 

30.11.16 21:42

150 Postings, 3789 Tage RainbowfuGut

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) just announced the submission of its New Drug Application (NDA) for Rexista, it?s bioequivalent OxyContin product. The application comes a little later than first expected, but it?s now in the bag, and the result could be a game changer for the company. It?s targeting an abuse deterrent approval, and if the agency gives the asset a thumbs up for approval, and couples the approval with an abuse deterrent label, it could attract significant investor attention to IntelliPharmaCeutics. There?s also a strong potential catalyst on a commercialization partner announcement for the drug, meaning at its current valuation of $96 million (and taking into consideration a somewhat muted response to the latest NDA filing, there looks to be some degree of potential for a discount entry.

The FDA is now set to make a decision on Valeant Pharmaceuticals (NYSE:VRX)'s psoriasis drug, Brodalumab, on February 16, 2017. The Market Exclusive Intelligence Team set its sights on uncovering the truth about the delay. If you are invested in the stock, or are trading the event, you won't want to miss what we found.
 

13.03.17 12:30

200 Postings, 3206 Tage tollist hier

noch wer investiert?  

14.03.17 13:56

200 Postings, 3206 Tage tollhallo

No Hype - just the Facts.  Your complete source of news and realtime quotes from the TSX, TSX-V, CSE, Montreal, Nasdaq, NYSE, Amex and OTC Markets.
so ne interessante aktie und keine da?

 

01.04.17 18:20

998 Postings, 2933 Tage Max_V.Hallo toll

ja, ich bin auch schon eine Weile investiert und sehr überzeugt.  

12.04.17 13:24
1

998 Postings, 2933 Tage Max_V.Revenues verdoppelt bis Q3 2017 Cash flow positiv!


Intellipharmaceutics Announces First Quarter 2017 Results

globenewswire.com/news-release/2017/04/11/959226/0/en/Intelliphar­maceutics-Announces-First-Quarter-2017-Results.html

 

12.05.17 16:46

200 Postings, 3206 Tage tollnews

No Hype - just the Facts.  Your complete source of news and realtime quotes from the TSX, TSX-V, CSE, Montreal, Nasdaq, NYSE, Amex and OTC Markets.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aIPCI-2469654  

07.06.17 20:10

200 Postings, 3206 Tage tollgute news

07.06.17 20:11

200 Postings, 3206 Tage tollhier

No Hype - just the Facts.  Your complete source of news and realtime quotes from the TSX, TSX-V, CSE, Montreal, Nasdaq, NYSE, Amex and OTC Markets.
 

27.07.17 17:21

4501 Postings, 3253 Tage centsucher...

Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista? (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

http://www.intellipharmaceutics.com/...sedetail.cfm?ReleaseID=1034629

 

Seite: 1 | 2  
   Antwort einfügen - nach oben
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln